Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery.

Soike MH, Logue J, Qasem S, Hughes RT, McTyre E, Su J, Triozzi P, Bendandi M, Lo HW, Ahmed T, O'Neill SS, Debinski W, Pasche B, Watabe K, Miller LD, Chan MD, Ruiz J.

Sci Rep. 2019 Oct 7;9(1):14385. doi: 10.1038/s41598-019-50298-7.

2.

Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA).

Soldevilla MM, Hervas S, Villanueva H, Lozano T, Rabal O, Oyarzabal J, Lasarte JJ, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F.

PLoS One. 2017 Sep 21;12(9):e0185169. doi: 10.1371/journal.pone.0185169. eCollection 2017.

3.

A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.

Inogés S, Tejada S, de Cerio AL, Gállego Pérez-Larraya J, Espinós J, Idoate MA, Domínguez PD, de Eulate RG, Aristu J, Bendandi M, Pastor F, Alonso M, Andreu E, Cardoso FP, Valle RD.

J Transl Med. 2017 May 12;15(1):104. doi: 10.1186/s12967-017-1202-z.

4.

Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy.

Lozano T, Soldevilla MM, Casares N, Villanueva H, Bendandi M, Lasarte JJ, Pastor F.

Biomaterials. 2016 Jun;91:73-80. doi: 10.1016/j.biomaterials.2016.03.007. Epub 2016 Mar 8.

PMID:
26999456
5.

MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells.

Soldevilla MM, Villanueva H, Casares N, Lasarte JJ, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F.

Oncotarget. 2016 Apr 26;7(17):23182-96. doi: 10.18632/oncotarget.8095.

6.

Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy.

Hervas-Stubbs S, Soldevilla MM, Villanueva H, Mancheño U, Bendandi M, Pastor F.

Oncotarget. 2016 Jan 26;7(4):4522-30. doi: 10.18632/oncotarget.6608.

7.

Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma.

Tusé D, Ku N, Bendandi M, Becerra C, Collins R Jr, Langford N, Sancho SI, López-Díaz de Cerio A, Pastor F, Kandzia R, Thieme F, Jarczowski F, Krause D, Ma JK, Pandya S, Klimyuk V, Gleba Y, Butler-Ransohoff JE.

Biomed Res Int. 2015;2015:648143. doi: 10.1155/2015/648143. Epub 2015 Sep 6.

8.

2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia.

Soldevilla MM, Villanueva H, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F.

Biomaterials. 2015 Oct;67:274-85. doi: 10.1016/j.biomaterials.2015.07.020. Epub 2015 Jul 14.

PMID:
26231918
9.

Idiotype vaccine production using hybridoma technology.

Inoges S, de Cerio AL, Villanueva H, Pastor F, Bendandi M.

Methods Mol Biol. 2014;1139:367-87. doi: 10.1007/978-1-4939-0345-0_30.

PMID:
24619694
10.

CD28 aptamers as powerful immune response modulators.

Pastor F, Soldevilla MM, Villanueva H, Kolonias D, Inoges S, de Cerio AL, Kandzia R, Klimyuk V, Gleba Y, Gilboa E, Bendandi M.

Mol Ther Nucleic Acids. 2013 Jun 11;2:e98. doi: 10.1038/mtna.2013.26.

11.

Dendritic cell vaccination in glioblastoma after fluorescence-guided resection.

Valle RD, de Cerio AL, Inoges S, Tejada S, Pastor F, Villanueva H, Gallego J, Espinos J, Aristu J, Idoate MA, Andreu E, Bendandi M.

World J Clin Oncol. 2012 Nov 10;3(11):142-9. doi: 10.5306/wjco.v3.i11.142.

12.

Successful idiotypic vaccination following stem cell allotransplant in lymphoma.

de Cerio AL, Inogés S, Ai WZ, Villanueva H, Pastor F, Soldevilla MM, Soria E, Bendandi M.

Leuk Lymphoma. 2013 Apr;54(4):881-4. doi: 10.3109/10428194.2012.721544. Epub 2012 Sep 5. No abstract available.

PMID:
22897725
13.

BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.

Villanueva H, de Cerio AL, Inoges S, Pastor F, Soldevilla MM, Bendandi M.

Expert Rev Vaccines. 2011 Dec;10(12):1661-9. doi: 10.1586/erv.11.132.

PMID:
22085168
14.

Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses.

Inoges S, de Cerio AL, Villanueva H, Pastor F, Soria E, Bendandi M.

World J Clin Oncol. 2011 Jun 10;2(6):237-44. doi: 10.5306/wjco.v2.i6.237.

15.

Idiotype vaccines for lymphoma therapy.

Inogés S, de Cerio AL, Villanueva H, Soria E, Pastor F, Bendandi M.

Expert Rev Vaccines. 2011 Jun;10(6):801-9. doi: 10.1586/erv.11.44. Review.

PMID:
21692701
16.

Stem cell transplant and idiotypic vaccination for B-cell malignancies.

Inoges S, Lopez-Diaz de Cerio A, Sampol A, Nieto J, Soria E, Villanueva H, Pastor F, Bendandi M.

Curr Top Med Chem. 2011;11(13):1653-60. Review.

17.

Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma.

Bendandi M, Marillonnet S, Kandzia R, Thieme F, Nickstadt A, Herz S, Fröde R, Inogés S, Lòpez-Dìaz de Cerio A, Soria E, Villanueva H, Vancanneyt G, McCormick A, Tusé D, Lenz J, Butler-Ransohoff JE, Klimyuk V, Gleba Y.

Ann Oncol. 2010 Dec;21(12):2420-7. doi: 10.1093/annonc/mdq256. Epub 2010 May 21.

18.

Hybridoma-Derived Idiotype Vaccine for Lymphoma: Approval Must Wait.

Bendandi M.

Pharmaceuticals (Basel). 2010 Mar 15;3(3):667-678. Review.

19.

Idiotype vaccines for human B-cell malignancies.

Inoges S, de Cerio AL, Soria E, Villanueva H, Pastor F, Bendandi M.

Curr Pharm Des. 2010 Jan;16(3):300-7. Review.

20.

Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.

Bendandi M.

Nat Rev Cancer. 2009 Sep;9(9):675-81. doi: 10.1038/nrc2717. Review.

21.

Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism?

García-Muñoz R, Panizo C, Bendandi M, Llorente L.

Leuk Res. 2009 Nov;33(11):1437-9. doi: 10.1016/j.leukres.2009.05.008. Epub 2009 Jun 11.

PMID:
19523686
22.

Prolonged idiotypic vaccination against follicular lymphoma.

Inoges S, Lopez-Diaz de Cerio A, Zabalegui N, Soria E, Villanueva H, Panizo C, Rodriguez-Caballero A, Suarez L, Pastor F, Rodriguez-Calvillo M, Orfao A, Bendandi M.

Leuk Lymphoma. 2009 Jan;50(1):47-53. doi: 10.1080/10428190802601122.

23.

Aiming at a curative strategy for follicular lymphoma.

Bendandi M.

CA Cancer J Clin. 2008 Sep-Oct;58(5):305-17. doi: 10.3322/CA.2008.0011. Epub 2008 Aug 28. Review.

24.

Splenic marginal zone lymphoma with Evans' syndrome, autoimmunity, and peripheral gamma/delta T cells.

García-Muñoz R, Rodriguez-Otero P, Pegenaute C, Merino J, Jakes-Okampo J, Llorente L, Bendandi M, Panizo C.

Ann Hematol. 2009 Feb;88(2):177-8. doi: 10.1007/s00277-008-0555-z. Epub 2008 Jul 30. No abstract available.

PMID:
18665362
25.

Clinical benefit of idiotype vaccines: too many trials for a clever demonstration?

Bendandi M.

Rev Recent Clin Trials. 2006 Jan;1(1):67-74. Review.

PMID:
18393782
26.

IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis.

Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, Lopez-Diaz de Cerio A, Palacios R, Sepulcre J, Moreno B, Gonzalez Z, Fernandez-Diez B, Melero I, Bendandi M, Villoslada P.

Eur J Immunol. 2008 Feb;38(2):576-86. doi: 10.1002/eji.200737271.

27.

Orthodontic extraction: riskless extraction of impacted lower third molars close to the mandibular canal.

Alessandri Bonetti G, Bendandi M, Laino L, Checchi V, Checchi L.

J Oral Maxillofac Surg. 2007 Dec;65(12):2580-6. No abstract available.

PMID:
18022488
28.

The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma.

Rodríguez J, Conde E, Gutiérrez A, Lahuerta JJ, Arranz R, Sureda A, Zuazu J, Fernández de Sevilla A, Bendandi M, Solano C, León A, Varela MR, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea, Spanish Lymphoma/Autologous Bone Marrow Transplant Study Group.

Haematologica. 2007 Aug;92(8):1067-74. Epub 2007 Jul 20.

29.

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group.

Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero MD; 'Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea' (GEL-TAMO).

Eur J Haematol. 2007 Jul;79(1):32-8.

PMID:
17598836
30.

[Anemia in chronic lymphatic leukemia: is erythropoietin the solution?].

de Gaona ER, Rifón J, Pérez-Calvo J, Bendandi M, Iglesias R, Panizo C.

Rev Med Univ Navarra. 2007 Jan-Mar;51(1):3-10. Review. Spanish.

PMID:
17555114
31.

Anti-idiotype antibodies in cancer treatment.

de Cerio AL, Zabalegui N, Rodríguez-Calvillo M, Inogés S, Bendandi M.

Oncogene. 2007 May 28;26(25):3594-602. Review.

32.

Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer.

Arina A, Murillo O, Dubrot J, Azpilikueta A, Alfaro C, Pérez-Gracia JL, Bendandi M, Palencia B, Hervás-Stubbs S, Melero I.

Expert Opin Biol Ther. 2007 May;7(5):599-615. Review.

33.

Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.

Redondo P, del Olmo J, López-Diaz de Cerio A, Inoges S, Marquina M, Melero I, Bendandi M.

J Invest Dermatol. 2007 Jul;127(7):1673-80. Epub 2007 Mar 22.

34.

Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.

Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Cañigral G, Bergua J, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea.

Eur J Haematol. 2007 Apr;78(4):290-6.

PMID:
17378891
35.

The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience.

Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero MD.

Ann Oncol. 2007 Apr;18(4):652-7. Epub 2007 Jan 17.

PMID:
17229774
36.

Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor.

Radcliffe CM, Arnold JN, Suter DM, Wormald MR, Harvey DJ, Royle L, Mimura Y, Kimura Y, Sim RB, Inogès S, Rodriguez-Calvillo M, Zabalegui N, de Cerio AL, Potter KN, Mockridge CI, Dwek RA, Bendandi M, Rudd PM, Stevenson FK.

J Biol Chem. 2007 Mar 9;282(10):7405-15. Epub 2006 Dec 29.

37.

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.

Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M; Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group; Programa para el Estudio y Tratamiento de Hemopatias Malignas study group.

J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301.

PMID:
16985248
38.

[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].

Alfaro C, Murillo O, Tirapu I, Azpilicueta A, Huarte E, Arina A, Arribillaga L, Pérez-Gracia JL, Bendandi M, Prieto J, Lasarte JJ, Melero I.

An Sist Sanit Navar. 2006 Jan-Apr;29(1):77-96. Review. Spanish.

39.

Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena.

Melero I, Arina A, Murillo O, Dubrot J, Alfaro C, Pérez-Gracia JL, Bendandi M, Hervás-Stubbs S.

Clin Cancer Res. 2006 Apr 15;12(8):2385-9. No abstract available.

40.

Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.

Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A.

Leuk Lymphoma. 2006 Jan;47(1):29-37.

PMID:
16321824
41.

[Past, present and future of anti-idiotype vaccination].

Rodríguez Calvillo M, Inogés S, López Díaz de Cerio A, Zabalegui N, Panizo C, Hernández M, Pérez Calvo J, Prósper F, Melero I, Sánchez-Ibarrola A, Rocha E, Bendandi M.

Rev Med Univ Navarra. 2004 Jul-Sep;48(3):14-23. Review. Spanish.

PMID:
15622921
42.

Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.

Mazzolini G, Alfaro C, Sangro B, Feijoó E, Ruiz J, Benito A, Tirapu I, Arina A, Sola J, Herraiz M, Lucena F, Olagüe C, Subtil J, Quiroga J, Herrero I, Sádaba B, Bendandi M, Qian C, Prieto J, Melero I.

J Clin Oncol. 2005 Feb 10;23(5):999-1010. Epub 2004 Dec 14.

43.

Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development.

Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Zabalegui N, Villanueva H, Bendandi M.

Crit Rev Oncol Hematol. 2004 Oct;52(1):1-7. Review.

PMID:
15363462
44.

Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses.

Panizo C, Pérez-Salazar M, Bendandi M, Rodríguez-Calvillo M, Boán JF, García-Velloso MJ, Richter J, Rocha E.

Leuk Lymphoma. 2004 Sep;45(9):1829-33.

PMID:
15223643
45.

[Active immunotherapy in the treatment of haematological neoplasias].

Inogés S, Rodríguez Calvillo M, López Díaz de Cerio A, Zabalegui N, Melero I, Sánchez Ibarrola A, Rocha E, Bendandi M.

An Sist Sanit Navar. 2004 Jan-Apr;27(1):45-62. Review. Spanish.

46.

Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies.

Zabalegui N, de Cerio AL, Inogés S, Rodríguez-Calvillo M, Pérez-Calvo J, Hernández M, García-Foncillas J, Martín-Algarra S, Rocha E, Bendandi M.

Haematologica. 2004 May;89(5):541-6.

47.

Challenging paradigms in lymphoma treatment.

Bendandi M, Pileri SA, Zinzani PL.

Ann Oncol. 2004 May;15(5):703-11. Review. No abstract available.

48.

The role of idiotype vaccines in the treatment of human B-cell malignancies.

Bendandi M.

Expert Rev Vaccines. 2004 Apr;3(2):163-70. Review.

PMID:
15056042
49.

A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients.

Pérez-Calvo J, Fernàndez O, Aristu JJ, Aramendia JM, Rifón J, Prosper F, Bendandi M, Rocha E, Martin-Algarra S.

Bone Marrow Transplant. 2004 Mar;33(5):499-502.

PMID:
14716344
50.

Feasibility of idiotype vaccination in relapsed B-cell malignancies.

Inogés S, Rodríguez-Calvillo M, López-Díaz de Cerio A, Zabalegui N, Pérez-Calvo J, Panizo C, Hernandez M, Cuesta B, Rocha E, Bendandi M.

Haematologica. 2003 Dec;88(12):1438-40. No abstract available.

Supplemental Content

Loading ...
Support Center